MedTrace Logo

Ectoin Lozenges (EHT02) in the Treatment of Oropharyngeal Allergic Symptoms

NCT03975257 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2019-12-10

No results posted yet for this study

Summary

The goal of this multicentric, prospective, randomised, controlled study (§23b German Act on Medical Devices (MPG)) is to investigate the efficacy of Ectoin Lozenges (EHT02) in treatment and prevention of oropharyngeal allergic symptoms.

Conditions

  • Allergy

Interventions

DEVICE

Medical Device: Ectoin Lozenge

Application of Ectoin Lozenge (EHT02) in accordance with the instructions for use

Sponsors & Collaborators

  • Bitop AG

    lead INDUSTRY

Principal Investigators

  • Andreas Bilstein, Dr. · CSO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-04
Primary Completion
2019-09-12
Completion
2019-09-12

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03975257 on ClinicalTrials.gov